Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Live Nonreplicating Smallpox And Monkeypox Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Bavarian Nordic
Deal Size : Undisclosed
Deal Type : Agreement
Details : JYNNEOS is a suspension for subcutaneous injection (0.5 mL) based on a live, attenuated vaccinia virus (Modified Vaccinia Ankara, MVA-BN), incapable of replicating in the body, yet still capable of eliciting a potent immune response.
Brand Name : Jynneos
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 19, 2022
Lead Product(s) : Live Nonreplicating Smallpox And Monkeypox Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Bavarian Nordic
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ad26.COV2-S
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Partnership
GRAM Partners with Johnson & Johnson on Manufacturing in Fight Against COVID-19
Details : The agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson's SARS-CoV-2 vaccine candidate.
Brand Name : JNJ-78436735
Molecule Type : Vaccine
Upfront Cash : Undisclosed
September 25, 2020
Lead Product(s) : Ad26.COV2-S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?